REVEAL: Limited Benefit Leaves Merck & Co Still Undecided On Anacetrapib's Future

The commercial future of Merck & Co's CETP inhibitor anacetrapib is still in limbo as the 9% reduction in the risk of CV events seen in REVEAL underwhelms. Filings look unlikely.